Literature DB >> 32804414

Synthesizing independent stagewise trials for optimal dynamic treatment regimes.

Yuan Chen1, Yuanjia Wang1, Donglin Zeng2.   

Abstract

Dynamic treatment regimes (DTRs) adaptively prescribe treatments based on patients' intermediate responses and evolving health status over multiple treatment stages. Data from sequential multiple assignment randomization trials (SMARTs) are recommended to be used for learning DTRs. However, due to re-randomization of the same patients over multiple treatment stages and a prolonged follow-up period, SMARTs are often difficult to implement and costly to manage, and patient adherence is always a concern in practice. To lessen such practical challenges, we propose an alternative approach to learn optimal DTRs by synthesizing independent trials over different stages. Specifically, at each stage, data from a single randomized trial along with patients' natural medical history and health status in previous stages are used. We use a backward learning method to estimate optimal treatment decisions at a particular stage, where patients' future optimal outcome increments are estimated using data observed from independent trials with future stages' information. Under some conditions, we show that the proposed method yields consistent estimation of the optimal DTRs and we obtain the same learning rates as those from SMARTs. We conduct simulation studies to demonstrate the advantage of the proposed method. Finally, we learn optimal DTRs for treating major depressive disorder (MDD) by stagewise synthesis of two randomized trials. We perform a validation study on independent subjects and show that the synthesized DTRs lead to the greatest MDD symptom reduction compared to alternative methods.
© 2020 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Q-function; adaptive treatment strategies; clinical trials; machine learning; personalized medicine

Mesh:

Year:  2020        PMID: 32804414      PMCID: PMC7814466          DOI: 10.1002/sim.8712

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  27 in total

1.  Composite interaction tree for simultaneous learning of optimal individualized treatment rules and subgroups.

Authors:  Xin Qiu; Yuanjia Wang
Journal:  Stat Med       Date:  2019-03-19       Impact factor: 2.373

2.  Developing adaptive treatment strategies in substance abuse research.

Authors:  Susan A Murphy; Kevin G Lynch; David Oslin; James R McKay; Tom TenHave
Journal:  Drug Alcohol Depend       Date:  2006-10-23       Impact factor: 4.492

3.  PERFORMANCE GUARANTEES FOR INDIVIDUALIZED TREATMENT RULES.

Authors:  Min Qian; Susan A Murphy
Journal:  Ann Stat       Date:  2011-04-01       Impact factor: 4.028

4.  Methods for synthesizing findings on moderation effects across multiple randomized trials.

Authors:  C Hendricks Brown; Zili Sloboda; Fabrizio Faggiano; Brent Teasdale; Ferdinand Keller; Gregor Burkhart; Federica Vigna-Taglianti; George Howe; Katherine Masyn; Wei Wang; Bengt Muthén; Peggy Stephens; Scott Grey; Tatiana Perrino
Journal:  Prev Sci       Date:  2013-04

5.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.

Authors:  Caicun Zhou; Yi-Long Wu; Gongyan Chen; Jifeng Feng; Xiao-Qing Liu; Changli Wang; Shucai Zhang; Jie Wang; Songwen Zhou; Shengxiang Ren; Shun Lu; Li Zhang; Chengping Hu; Chunhong Hu; Yi Luo; Lei Chen; Ming Ye; Jianan Huang; Xiuyi Zhi; Yiping Zhang; Qingyu Xiu; Jun Ma; Li Zhang; Changxuan You
Journal:  Lancet Oncol       Date:  2011-07-23       Impact factor: 41.316

6.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

Authors:  Alan Sandler; Robert Gray; Michael C Perry; Julie Brahmer; Joan H Schiller; Afshin Dowlati; Rogerio Lilenbaum; David H Johnson
Journal:  N Engl J Med       Date:  2006-12-14       Impact factor: 91.245

Review 7.  Second-line treatments in non-small cell lung cancer. A systematic review of literature and metaanalysis of randomized clinical trials.

Authors:  Davide Tassinari; Emanuela Scarpi; Sergio Sartori; Emiliano Tamburini; Carlotta Santelmo; Paola Tombesi; Luigi Lazzari-Agli
Journal:  Chest       Date:  2009-02-18       Impact factor: 9.410

8.  New Statistical Learning Methods for Estimating Optimal Dynamic Treatment Regimes.

Authors:  Ying-Qi Zhao; Donglin Zeng; Eric B Laber; Michael R Kosorok
Journal:  J Am Stat Assoc       Date:  2015       Impact factor: 5.033

9.  Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis.

Authors:  Andrea Ardizzoni; Luca Boni; Marcello Tiseo; Frank V Fossella; Joan H Schiller; Marianne Paesmans; Davorin Radosavljevic; Adriano Paccagnella; Petr Zatloukal; Paola Mazzanti; Donald Bisset; Rafael Rosell
Journal:  J Natl Cancer Inst       Date:  2007-06-06       Impact factor: 13.506

10.  REVAMP - Research Evaluating the Value of Augmenting Medication with Psychotherapy: rationale and design.

Authors:  Madhukar H Trivedi; James H Kocsis; Michael E Thase; David W Morris; Stephen R Wisniewski; Andrew C Leon; Alan J Gelenberg; Daniel N Klein; George Niederehe; Alan F Schatzberg; Philip T Ninan; Martin B Keller
Journal:  Psychopharmacol Bull       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.